Prevention and Remediation of Insulin Multimorbidity in Europe

Cologne, December 12, 2024 – The PRIME project, a groundbreaking research initiative focused on advancing our knowledge on the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions, is holding its final meeting today and tomorrow in Cologne. This milestone event marks the conclusion of years of dedicated work, as researchers, industry partners, and stakeholders gather to present the project’s outcomes and discuss its far-reaching implications.

During the meeting, participants are showcasing the key results achieved by the project, which have significantly advanced knowledge and applications in this vital research area. From novel methodologies to practical solutions, PRIME has laid a strong foundation for future innovations, with its findings already influencing academic circles and industry practices.

As attendees reflect on the project’s success, a bittersweet atmosphere prevails. Many expressed sadness at the formal end of the initiative, which has fostered remarkable collaborations and breakthroughs. Prof. Barbara Franke, coordinator of the project, noted, “PRIME has not only been a hub of innovation but also a vibrant community of passionate experts. It’s hard to say goodbye to this chapter, but we’re excited about the doors it has opened.”

Despite the project’s conclusion, there is widespread optimism about the continuation of research in this critical field. Efforts are already underway to secure new funding and partnerships to build on PRIME’s legacy. As Prof. Franke emphasized, “The work doesn’t stop here. PRIME has shown us what’s possible, and we are committed to pushing these boundaries even further.”

The two-day meeting will conclude with a discussion of strategies for sustaining momentum in the research field, ensuring that PRIME’s impact will be felt for years to come.